Literature DB >> 31582380

MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer.

Jae Ho Seo1,2, Young Chan Chae3,2,4, Andrew V Kossenkov5, Yu Geon Lee4, Hsin-Yao Tang5, Ekta Agarwal1,2, Dmitry I Gabrilovich1,2, Lucia R Languino1,6, David W Speicher1,5,7, Prashanth K Shastrula8, Alessandra Maria Storaci9,10, Stefano Ferrero9,11, Gabriella Gaudioso9, Manuela Caroli12, Davide Tosi13, Massimo Giroda14, Valentina Vaira9,10, Vito W Rebecca7, Meenhard Herlyn7, Min Xiao7, Dylan Fingerman7, Alessandra Martorella7, Emmanuel Skordalakes8, Dario C Altieri3,2.   

Abstract

The regulators of mitochondrial cell death in cancer have remained elusive, hampering the development of new therapies. Here, we showed that protein isoforms of mitochondrial fission factor (MFF1 and MFF2), a molecule that controls mitochondrial size and shape, that is, mitochondrial dynamics, were overexpressed in patients with non-small cell lung cancer and formed homo- and heterodimeric complexes with the voltage-dependent anion channel-1 (VDAC1), a key regulator of mitochondrial outer membrane permeability. MFF inserted into the interior hole of the VDAC1 ring using Arg225, Arg236, and Gln241 as key contact sites. A cell-permeable MFF Ser223-Leu243 d-enantiomeric peptidomimetic disrupted the MFF-VDAC1 complex, acutely depolarized mitochondria, and triggered cell death in heterogeneous tumor types, including drug-resistant melanoma, but had no effect on normal cells. In preclinical models, treatment with the MFF peptidomimetic was well-tolerated and demonstrated anticancer activity in patient-derived xenografts, primary breast and lung adenocarcinoma 3D organoids, and glioblastoma neurospheres. These data identify the MFF-VDAC1 complex as a novel regulator of mitochondrial cell death and an actionable therapeutic target in cancer. SIGNIFICANCE: These findings describe mitochondrial fission regulation using a peptidomimetic agent that disturbs the MFF-VDAC complex and displays anticancer activity in multiple tumor models.See related commentary by Rao, p. 6074. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31582380      PMCID: PMC6911621          DOI: 10.1158/0008-5472.CAN-19-1982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis.

Authors:  John G Pastorino; Nataly Shulga; Jan B Hoek
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

2.  Dual face apoptotic machinery: from initiator of apoptosis to guardian of necroptosis.

Authors:  Wim Declercq; Nozomi Takahashi; Peter Vandenabeele
Journal:  Immunity       Date:  2011-10-28       Impact factor: 31.745

3.  Functional dynamics in the voltage-dependent anion channel.

Authors:  Saskia Villinger; Rodolfo Briones; Karin Giller; Ulrich Zachariae; Adam Lange; Bert L de Groot; Christian Griesinger; Stefan Becker; Markus Zweckstetter
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-10       Impact factor: 11.205

Review 4.  Mitochondrial dynamics in adaptive and maladaptive cellular stress responses.

Authors:  Verónica Eisner; Martin Picard; György Hajnóczky
Journal:  Nat Cell Biol       Date:  2018-06-27       Impact factor: 28.824

5.  Identifying the components of the elusive mitochondrial permeability transition pore.

Authors:  Jason Karch; Jeffery D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

Review 6.  VDAC structure, selectivity, and dynamics.

Authors:  Marco Colombini
Journal:  Biochim Biophys Acta       Date:  2012-01-03

7.  Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Authors:  Triona Ni Chonghaile; Kristopher A Sarosiek; Thanh-Trang Vo; Jeremy A Ryan; Anupama Tammareddi; Victoria Del Gaizo Moore; Jing Deng; Kenneth C Anderson; Paul Richardson; Yu-Tzu Tai; Constantine S Mitsiades; Ursula A Matulonis; Ronny Drapkin; Richard Stone; Daniel J Deangelo; David J McConkey; Stephen E Sallan; Lewis Silverman; Michelle S Hirsch; Daniel Ruben Carrasco; Anthony Letai
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

Review 8.  Regulated necrosis: disease relevance and therapeutic opportunities.

Authors:  Marcus Conrad; José Pedro Friedmann Angeli; Peter Vandenabeele; Brent R Stockwell
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma.

Authors:  Andrea Di Cristofori; Stefano Ferrero; Irene Bertolini; Gabriella Gaudioso; Maria Veronica Russo; Valeria Berno; Marco Vanini; Marco Locatelli; Mario Zavanone; Paolo Rampini; Thomas Vaccari; Manuela Caroli; Valentina Vaira
Journal:  Oncotarget       Date:  2015-07-10
View more
  13 in total

1.  COA3 overexpression promotes non-small cell lung cancer metastasis by reprogramming glucose metabolism.

Authors:  Hongwei Lin; Yanjun Gao; Kang Sun; Qian Zhang; Yujuan Li; Min Chen; Faguang Jin
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

2.  VDAC1 negatively regulates melanogenesis through the Ca2+-calcineurin-CRTC1-MITF pathway.

Authors:  Jianli Wang; Juanjuan Gong; Qiaochu Wang; Tieshan Tang; Wei Li
Journal:  Life Sci Alliance       Date:  2022-06-01

3.  Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.

Authors:  Yutong Fang; Junpeng Liu; Qunchen Zhang; Chuanghong She; Rongji Zheng; Rendong Zhang; Zexiao Chen; Chunfa Chen; Jundong Wu
Journal:  World J Surg Oncol       Date:  2022-06-22       Impact factor: 3.253

4.  The TLK1/Nek1 axis contributes to mitochondrial integrity and apoptosis prevention via phosphorylation of VDAC1.

Authors:  Vibha Singh; Md Imtiaz Khalil; Arrigo De Benedetti
Journal:  Cell Cycle       Date:  2020-01-09       Impact factor: 4.534

Review 5.  Potential Mechanism Underlying the Role of Mitochondria in Breast Cancer Drug Resistance and Its Related Treatment Prospects.

Authors:  Yuefeng Li; Zhian Li
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

6.  Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response.

Authors:  Saurabh K Garg; Eric A Welsh; Bin Fang; Yuliana I Hernandez; Trevor Rose; Jhanelle Gray; John M Koomen; Anders Berglund; James J Mulé; Joseph Markowitz
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

7.  Mitochondrial Fission Factor Is a Novel Interacting Protein of the Critical B Cell Survival Regulator TRAF3 in B Lymphocytes.

Authors:  Yingying Liu; Samantha Gokhale; Jaeyong Jung; Sining Zhu; Chang Luo; Debanjan Saha; Jessie Yanxiang Guo; Huaye Zhang; Saw Kyin; Wei-Xing Zong; Eileen White; Ping Xie
Journal:  Front Immunol       Date:  2021-10-20       Impact factor: 8.786

Review 8.  Mitochondrial Fission and Fusion in Tumor Progression to Metastasis.

Authors:  Dillon P Boulton; M Cecilia Caino
Journal:  Front Cell Dev Biol       Date:  2022-03-09

Review 9.  Role of Mitochondrial Stress Response in Cancer Progression.

Authors:  Yu Geon Lee; Do Hong Park; Young Chan Chae
Journal:  Cells       Date:  2022-02-23       Impact factor: 6.600

10.  Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity.

Authors:  Rosa Sánchez-Alvarez; Ernestina Marianna De Francesco; Marco Fiorillo; Federica Sotgia; Michael P Lisanti
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.